Sushma Jonna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sushma Jonna has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Y. Deneka
Fox Chase Cancer Center, Philadelphia, PA
1 shared publication - Erica A. Golemis
Program in Cancer Signaling and Microenvironment, Fox Chase Cancer Center, Philadelphia, USA
1 shared publication - Hossein Borghaei
Fox Chase Cancer Center, Philadelphia, PA
1 shared publication - Jyoti D. Patel
Northwestern University, Chicago, IL
1 shared publication - Karam Khaddour
Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
1 shared publication - Mohamed E. Abazeed
Department of Radiation Oncology, Northwest Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
1 shared publication
Latest Publications
- Open Access
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent and acquired resistance constitute a major challenge to the longitudinal treatment. Ongoing work is aimed at understanding the molecular basis of these resistance mechanisms, with exciting new studies evaluating novel agents and combination therapies to improve control of tumors with all forms of EGFR mutation. In this review, we first provide a discussion of EGFR-mutated lung cancer and the efficacy of available EGFR TKIs in the clinical setting against both common and rare EGFR mutations. Second, we discuss common resistance mechanisms that lead to therapy failure during treatment with EGFR TKIs. Third, we review novel approaches aimed at improving outcomes and overcoming resistance to EGFR TKIs. Finally, we highlight recent breakthroughs in the use of EGFR TKIs in non-metastatic EGFR-mutated lung cancer.
Open AccessTargeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent and acquired resistance constitute a major challenge to the longitudinal treatment. Ongoing work is aimed at understanding the molecular basis of these resistance mechanisms, with exciting new studies evaluating novel agents and combination therapies to improve control of tumors with all forms of EGFR mutation. In this review, we first provide a discussion of EGFR-mutated lung cancer and the efficacy of available EGFR TKIs in the clinical setting against both common and rare EGFR mutations. Second, we discuss common resistance mechanisms that lead to therapy failure during treatment with EGFR TKIs. Third, we review novel approaches aimed at improving outcomes and overcoming resistance to EGFR TKIs. Finally, we highlight recent breakthroughs in the use of EGFR TKIs in non-metastatic EGFR-mutated lung cancer.